Involvement of STAT3 in immune evasion during lung tumorigenesis

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Kida, Hiroshi ^a   Ihara, Shoichi ^a   Kumanogoh, Atsushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunity; Lung; MHC class I; MICA; NK cell; STAT3; Tumorigenesis

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RANTES; RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GROWTH INHIBITION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; LUNG CANCER; LUNG CARCINOGENESIS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 84886945726     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22653     Document Type: Article

References (10)

1. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295-303 PMID:10458605; http://dx.doi.org/10.1016/S0092-8674(00)81959-5.
2. Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366:1905-13; PMID:22591296; http://dx.doi.org/10.1056/NEJMoa1114885.
3. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10:127-40; PMID:21283107; http:// dx.doi.org/10.1038/nrd3264.
4. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in nonsmall cell lung carcinoma. PLoS One 2012; 7:e30820; PMID:22319590; http://dx.doi.org/10.1371/journal. pone.0030820.
5. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51 PMID:17186030; http://dx.doi.org/10.1038/nri1995.
6. Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, Kimura T, et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res 2012; 72:2990-9; PMID:22659452; http://dx.doi.org/10.1158/0008-5472.CAN-11-4062.
7. Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005; 105:2428-35; PMID:15536145; http://dx.doi.org/10.1182/blood-2004-09-3458.
8. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http:// dx.doi.org/10.1038/nrc2734.
9. Bluestone JA, Small EJ. The future of cancer treatment: will it include immunotherapy Cancer Cell 2012; 22:7-8; PMID:22789534; http://dx.doi.org/10.1016/j. ccr.2012.06.009.
10. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Förster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10:39-49; PMID:10023769; http://dx.doi.org/10.1016/S1074-7613(00)80005-9.